中源协和(600645) - 2025 Q2 - 季度财报

Definitions Definitions of Common Terms This chapter defines key terms, regulatory bodies, company entities, biotechnology terms, and reporting periods for clear understanding of the report content - The report defines key entities and professional terms such as China Securities Regulatory Commission (CSRC), the Company, Jiadao Success, Deyuan Health, OriGene Technologies, Inc., In Vitro Diagnostics (IVD), Mesenchymal Stem Cells (MSC), induced Pluripotent Stem Cells (iPSC), National Medical Products Administration (NMPA), Center for Drug Evaluation (CDE), and Food and Drug Administration (FDA)[15] Company Profile and Key Financial Indicators This section provides an overview of the company's basic information and key financial performance indicators Company Information This section presents the company's fundamental registration details, including its Chinese name, abbreviation, foreign name, and legal representative Company Basic Information | Metric | Content | | :--- | :--- | | Chinese Name | 中源协和细胞基因工程股份有限公司 | | Chinese Abbreviation | 中源协和 | | Foreign Name | VCANBIO CELL & GENE ENGINEERING CORP., LTD | | Legal Representative | WANG HONGQI（王洪琦） | Contacts and Contact Information This section provides contact information for the company's Board Secretary and Securities Affairs Representative, including names, addresses, phone numbers, faxes, and email addresses Contact Information | Position | Name | Contact Address | Phone | Fax | Email | | :--- | :--- | :--- | :--- | :--- | :--- | | Board Secretary | 陈轶青 | 天津市滨海高新区华苑产业区梅苑路12号 | 022-58617160 | 022-58617161 | zhongyuanxiehe@vcanbio.com | | Securities Affairs Representative | 张奋 | 天津市滨海高新区华苑产业区梅苑路12号 | 022-58617160 | 022-58617161 | zhongyuanxiehe@vcanbio.com | Brief Introduction to Changes in Basic Information This section outlines the company's current registered and office addresses, noting that historical changes are available in company announcements - The company's registered address is Floor 2, Building A, No. 12 Meiyuan Road, Huayuan Industrial Zone, Binhai High-tech Zone, Tianjin, and its office address is No. 12 Meiyuan Road, Huayuan Industrial Zone, Binhai High-tech Zone, Tianjin[17] Brief Introduction to Changes in Information Disclosure and Document Custody Locations This section specifies the company's designated newspapers for information disclosure, the website for report publication, and the location for report availability - The company designates "China Securities Journal", "Shanghai Securities News", and "Securities Times" as its information disclosure newspapers, with the semi-annual report published on www.sse.com.cn and available at No. 12 Meiyuan Road, Huayuan Industrial Zone, Binhai High-tech Zone, Tianjin[18] Overview of Company Shares This section provides a brief overview of the company's A-share stock, including its listing exchange, abbreviation, and code Company Stock Overview | Share Type | Listing Exchange | Stock Abbreviation | Stock Code | | :--- | :--- | :--- | :--- | | A股 | 上海证券交易所 | 中源协和 | 600645 | Company's Key Accounting Data and Financial Indicators This section presents the company's key accounting data and financial indicators for the current and prior periods, explaining the reasons for profit decline Key Accounting Data (Unit: yuan) | Item | Current Period (Jan-Jun) | Prior Period | Change from Prior Period (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 716,369,723.52 | 802,285,328.09 | -10.71 | | Total Profit | 74,744,079.80 | 114,140,321.07 | -34.52 | | Net Profit Attributable to Shareholders | 57,770,452.54 | 85,185,087.67 | -32.18 | | Net Cash Flow from Operating Activities | 123,036,717.91 | 98,635,675.90 | 24.74 | Key Financial Indicators (Unit: yuan/share) | Item | Current Period (Jan-Jun) | Prior Period | Change from Prior Period (%) | | :--- | :--- | :--- | :--- | | Basic EPS | 0.13 | 0.18 | -27.78 | | Diluted EPS | 0.13 | 0.18 | -27.78 | | Basic EPS after Non-recurring Gain/Loss | 0.12 | 0.18 | -33.33 | | Weighted Avg. ROE (%) | 1.59 | 2.32 | 减少0.73个百分点 | - The company's total profit, net profit attributable to shareholders, and net profit attributable to shareholders after non-recurring gain/loss decreased from the prior period, primarily due to a decline in reagent segment revenue and a year-on-year decrease in net profit[23] Non-recurring Gain/Loss Items and Amounts This section details the non-recurring gain/loss items and their amounts for the reporting period, totaling 3.88 million yuan Non-recurring Gain/Loss Items and Amounts (Unit: yuan) | Non-recurring Gain/Loss Item | Amount | | :--- | :--- | | Gain/Loss on Disposal of Non-current Assets | -332,722.36 | | Government Grants Recognized in Current P&L | 1,163,733.71 | | Fair Value Change G/L & Disposal G/L from Fin. Assets/Liabilities | 5,000,290.13 | | Reversal of Impairment for Receivables Individually Assessed | 351,418.58 | | Other Non-operating Income & Expenses | -223,827.70 | | Other Non-recurring G/L Items | -1,543,812.26 | | Less: Income Tax Impact | 370,288.98 | | Minority Interest Impact (After Tax) | 166,023.23 | | Total | **